Table 1.
Baseline characteristics of the participants of each group in the initial and extended phase.
| Primary Series (IM-IM)-Booster (ID) | Types of Vaccines | ||||
|---|---|---|---|---|---|
| All | CoronaVac- BNT162b2 |
CoronaVac- ChAdOx1 |
ChAdOx1-BNT162b2 | p-Value | |
| Number of subjects, n (%) | 135 (100.0) | 45 (33.3) | 45 (33.3) | 45 (33.3) | - |
| Age (years), median (IQR) | 39.0 (30.0, 46.0) | 38.0 (29.0, 44.0) | 39.0 (29.0, 45.0) | 43.0 (30.0, 50.0) | 0.186 |
| Male, n (%) | 60 (44.4) | 18 (30.0) | 23 (38.3) | 19 (31.7) | 0.533 |
| Body mass index: BMI (kg/m2), median (IQR) | 24.0 (21.5, 26.6) | 24.4 (22.3, 26.8) | 23.6 (20.4, 26.5) | 23.9 (21.5, 26.4) | 0.719 |
| Interval between last dose of primary series and booster (weeks), median (IQR) | 9.9 (7.4, 12.0) | 11.6 (8.9, 16.3) | 10.3 (9.1, 12.6) | 7.4 (6.0, 9.6) | 0.083 |